178 related articles for article (PubMed ID: 32160077)
1. Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical Implications.
Biran N; Vesole DH; Donato ML; Ip A; Kaur G; Goldberg S; Siegel DS
J Clin Oncol; 2020 Apr; 38(12):1367-1368. PubMed ID: 32160077
[No Abstract] [Full Text] [Related]
2. Understanding high-risk smoldering multiple myeloma.
Kreiniz N; Gertz MA
Leuk Lymphoma; 2023; 64(8):1361-1372. PubMed ID: 37229535
[TBL] [Abstract][Full Text] [Related]
3. The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact.
Kunacheewa C; Manasanch EE
Expert Rev Hematol; 2021 Dec; 14(12):1059-1069. PubMed ID: 34550841
[TBL] [Abstract][Full Text] [Related]
4. The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt.
Mohyuddin GR; Ouchveridze E; Goodman A; Prasad V
Leuk Lymphoma; 2021 Nov; 62(11):2793-2795. PubMed ID: 34114943
[No Abstract] [Full Text] [Related]
5. Persistent challenges with treating multiple myeloma early.
Goodman AM; Kim MS; Prasad V
Blood; 2021 Jan; 137(4):456-458. PubMed ID: 33236046
[TBL] [Abstract][Full Text] [Related]
6. Should high risk smoldering myeloma be treated outside a clinical trial: NO.
Gertz MA; Vaxman I
Leuk Lymphoma; 2021 Nov; 62(11):2565-2567. PubMed ID: 34261405
[No Abstract] [Full Text] [Related]
7. Smoldering Myeloma and the Art of War.
Lonial S; Dhodapkar MV; Rajkumar SV
J Clin Oncol; 2020 Jul; 38(21):2363-2365. PubMed ID: 32463739
[No Abstract] [Full Text] [Related]
8. Regression of smoldering myeloma with treatment of Gaucher disease.
Barley K; Parekh A; Salam S; Mendu DR; Shukla RP; Vatti D; Verina D; Stauffer C; Salib C; El Jamal S; Teruya-Feldstein J; Duffield AS; Leshchenko VV; Jagannath S; Balwani M; Parekh S
Blood Adv; 2024 Apr; 8(7):1634-1638. PubMed ID: 38285963
[No Abstract] [Full Text] [Related]
9. Serum markers alone can define high-risk smouldering multiple myeloma: new insights from the Czech Myeloma Group model.
Sørrig R
Br J Haematol; 2020 Jul; 190(2):137-138. PubMed ID: 32220013
[No Abstract] [Full Text] [Related]
10. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.
Sklavenitis-Pistofidis R; Aranha MP; Redd RA; Baginska J; Haradhvala NJ; Hallisey M; Dutta AK; Savell A; Varmeh S; Heilpern-Mallory D; Ujwary S; Zavidij O; Aguet F; Su NK; Lightbody ED; Bustoros M; Tahri S; Mouhieddine TH; Wu T; Flechon L; Anand S; Rosenblatt JM; Zonder J; Vredenburgh JJ; Boruchov A; Bhutani M; Usmani SZ; Matous J; Yee AJ; Jakubowiak A; Laubach J; Manier S; Nadeem O; Richardson P; Badros AZ; Mateos MV; Trippa L; Getz G; Ghobrial IM
Cancer Cell; 2022 Nov; 40(11):1358-1373.e8. PubMed ID: 36379208
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of systemic sclerosis coexisting with smoldering myeloma.
Smoleńska Ż; Gogulska Z; Dorniak K; Zdrojewski Z
Pol Arch Intern Med; 2021 Dec; 131(12):. PubMed ID: 34698468
[No Abstract] [Full Text] [Related]
12. Risk Stratification of Precursors to Multiple Myeloma in 2020.
Chudasama R; Barth P
R I Med J (2013); 2020 Apr; 103(3):46-47. PubMed ID: 32236162
[TBL] [Abstract][Full Text] [Related]
13. The impact of CD56 expression in smoldering myeloma patients on early progression.
Notarfranchi L; Segreto R; Vescovini R; Dalla Palma AB; Marchica V; Burroughs-Garcia J; Toscani D; Todaro G; Raimondi V; Iannozzi NT; Bonomini S; Sammarelli G; Craviotto L; Pedrazzoni M; Storti P; Giuliani N
Hematol Oncol; 2023 Aug; 41(3):587-589. PubMed ID: 36441875
[No Abstract] [Full Text] [Related]
14. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
[TBL] [Abstract][Full Text] [Related]
15. Smoldering Myeloma Treatment: Who, What, and When.
Mejia Saldarriaga M; Rossi A
Cancer J; 2021 May-Jun 01; 27(3):185-189. PubMed ID: 34549905
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial.
Nooka AK; Wang ML; Yee AJ; Kaufman JL; Bae J; Peterkin D; Richardson PG; Raje NS
JAMA Oncol; 2018 Dec; 4(12):e183267. PubMed ID: 30128502
[TBL] [Abstract][Full Text] [Related]
17. Applying current smouldering myeloma risk models to a UK single-centre cohort and clinical features at progression.
Ainley L; Camilleri M; Chavda SJ; McMillan A; Lee L; Popat R; Sillito F; Yong K
Br J Haematol; 2022 Mar; 196(6):e63-e66. PubMed ID: 34812509
[No Abstract] [Full Text] [Related]
18. Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.
Sundararajan S; Kumar A; Korde N; Agarwal A
Curr Hematol Malig Rep; 2016 Apr; 11(2):102-10. PubMed ID: 26894382
[TBL] [Abstract][Full Text] [Related]
19. State of the science in smoldering myeloma: Should we be treating in the clinic?
Hill E; Dew A; Kazandjian D
Semin Oncol; 2019 Apr; 46(2):112-120. PubMed ID: 31072611
[TBL] [Abstract][Full Text] [Related]
20. The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.
Caers J; Fernández de Larrea C; Leleu X; Heusschen R; Zojer N; Decaux O; Kastritis E; Minnema M; Jurczyszyn A; Beguin Y; Wäsch R; Palumbo A; Dimopoulos M; Mateos MV; Ludwig H; Engelhardt M
Oncologist; 2016 Mar; 21(3):333-42. PubMed ID: 26921288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
